哌柏西利-话题@MedSci

#哌柏西利#

2篇内容 | 1583人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2256297, encodeId=fe08225629e75, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=553b639416e' target=_blank style='color:#2F92EE;'>#氟维司群#</a> <a href='/topic/show?id=46043990410' target=_blank style='color:#2F92EE;'>#哌柏西利#</a> <a href='/topic/show?id=e7241251448f' target=_blank style='color:#2F92EE;'>#伊那利塞#</a>, objectTitle=国内首个批准罗氏PI3Kα抑制剂伊那利塞片上市！用于治疗PIK3CA突变、HR+/HER2-乳腺癌！, objectType=article, longId=867505, objectId=6ffd86e50597, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20250227/ca695b1b8acc42fca5156d6084e84d07-u7oA6t2PYz8s.jpg, objectUrl=/article/show_article.do?id=6ffd86e50597, replyNumber=0, likeNumber=12, createdTime=2025-03-16, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6ffd86e50597, moduleTitle=国内首个批准罗氏PI3Kα抑制剂伊那利塞片上市！用于治疗PIK3CA突变、HR+/HER2-乳腺癌！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ffd86e50597)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209140, encodeId=355a2209140ac, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a> <a href='/topic/show?id=46043990410' target=_blank style='color:#2F92EE;'>#哌柏西利#</a>, objectTitle=NPJ：首例原发性EGFR 19del/CDK4扩增NSCLC获益奥希替尼联合哌柏西利, objectType=article, longId=829483, objectId=af2382948339, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240609/1717926604320_5579292.png, objectUrl=/article/show_article.do?id=af2382948339, replyNumber=0, likeNumber=121, createdTime=2024-06-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=af2382948339, moduleTitle=NPJ：首例原发性EGFR 19del/CDK4扩增NSCLC获益奥希替尼联合哌柏西利, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af2382948339)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2191640, encodeId=45622191640e7, content=<a href='/topic/show?id=1e6d11199964' target=_blank style='color:#2F92EE;'>#神经母细胞瘤细胞#</a> <a href='/topic/show?id=46043990410' target=_blank style='color:#2F92EE;'>#哌柏西利#</a> <a href='/topic/show?id=4f41e9094e5' target=_blank style='color:#2F92EE;'>#维甲酸#</a>, objectTitle=Dev Cell：哌柏西利显著提高神经母细胞瘤分化，有望改善现有疗法, objectType=article, longId=816151, objectId=917c81615172, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240305/e6fd7059808748b0be024d7b7afa31b6-S0VRz8dtw8du.jpg, objectUrl=/article/show_article.do?id=917c81615172, replyNumber=0, likeNumber=115, createdTime=2024-03-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=917c81615172, moduleTitle=Dev Cell：哌柏西利显著提高神经母细胞瘤分化，有望改善现有疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=917c81615172)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=919033, encodeId=402a919033f9, content=<a href='/topic/show?id=46043990410' target=_blank style='color:#2F92EE;'>#哌柏西利#</a>, objectTitle=Ann Oncol：二度失利！哌柏西利先发优势再遭挑战？, objectType=article, longId=206013, objectId=009220601305, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021121/1611222184132_5295905.jpg, objectUrl=/article/show_article.do?id=009220601305, replyNumber=0, likeNumber=116, createdTime=2021-01-22, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=009220601305, moduleTitle=Ann Oncol：二度失利！哌柏西利先发优势再遭挑战？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=009220601305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=918813, encodeId=7fb391881363, content=<a href='/topic/show?id=46043990410' target=_blank style='color:#2F92EE;'>#哌柏西利#</a>, objectTitle=爱博新，腰斩降价, objectType=article, longId=206009, objectId=f0832060090e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021121/1611221349284_5295905.jpg, objectUrl=/article/show_article.do?id=f0832060090e, replyNumber=0, likeNumber=137, createdTime=2021-01-21, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0832060090e, moduleTitle=爱博新，腰斩降价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0832060090e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

哌柏西利

2020-05-29

梅斯管理员

#乳腺癌# #氟维司群# #哌柏西利# #伊那利塞#

国内首个批准罗氏PI3Kα抑制剂伊那利塞片上市！用于治疗PIK3CA突变、HR+/HER2-乳腺癌！

2025-03-16发表于上海

梅斯管理员

#非小细胞肺癌# #NSCLC# #奥希替尼# #哌柏西利#

NPJ：首例原发性EGFR 19del/CDK4扩增NSCLC获益奥希替尼联合哌柏西利

2024-06-09发表于上海

梅斯管理员

#神经母细胞瘤细胞# #哌柏西利# #维甲酸#

Dev Cell：哌柏西利显著提高神经母细胞瘤分化，有望改善现有疗法

2024-03-07发表于威斯康星

lifefamily

#哌柏西利#

Ann Oncol：二度失利！哌柏西利先发优势再遭挑战？

2021-01-22

zb1235672

#哌柏西利#

爱博新，腰斩降价

2021-01-21

科室
- - 订阅+
  - 更多科室
工具
服务